These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 9547132)

  • 81. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients.
    Kavoussi RJ; Segraves RT; Hughes AR; Ascher JA; Johnston JA
    J Clin Psychiatry; 1997 Dec; 58(12):532-7. PubMed ID: 9448656
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Treatment of clozapine-induced obsessive-compulsive symptoms with sertraline.
    Allen L; Tejera C
    Am J Psychiatry; 1994 Jul; 151(7):1096-7. PubMed ID: 8010373
    [No Abstract]   [Full Text] [Related]  

  • 83. Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder.
    Murdoch D; McTavish D
    Drugs; 1992 Oct; 44(4):604-24. PubMed ID: 1281075
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Sertraline in the treatment of panic disorder: a double-blind multicenter trial.
    Pohl RB; Wolkow RM; Clary CM
    Am J Psychiatry; 1998 Sep; 155(9):1189-95. PubMed ID: 9734541
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study.
    Atmaca M; Kuloglu M; Tezcan E; Gecici O
    Int Clin Psychopharmacol; 2002 May; 17(3):115-9. PubMed ID: 11981352
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder.
    Fineberg NA; Pampaloni I; Pallanti S; Ipser J; Stein DJ
    Int Clin Psychopharmacol; 2007 Nov; 22(6):313-22. PubMed ID: 17917549
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.
    Diniz JB; Shavitt RG; Fossaluza V; Koran L; Pereira CA; Miguel EC
    J Clin Psychopharmacol; 2011 Dec; 31(6):763-8. PubMed ID: 22020357
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice.
    Ekselius L; von Knorring L; Eberhard G
    Int Clin Psychopharmacol; 1997 Nov; 12(6):323-31. PubMed ID: 9547134
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Personality traits as predictors for treatment response to sertraline among unmedicated obsessive-compulsive Disorder: A 12-weeks retrospective longitudinal study.
    Zhang J; Zhong H; Zhang Y; Yin J; Song X; Ye K; Song Z; Lai S; Zhong S; Wang Z; Jia Y
    J Psychiatr Res; 2024 Feb; 170():245-252. PubMed ID: 38171218
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Serotonin reuptake blockers for the treatment of obsessional jealousy.
    Stein DJ; Hollander E; Josephson SC
    J Clin Psychiatry; 1994 Jan; 55(1):30-3. PubMed ID: 8294389
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Are patients who are intolerant to one SSRI intolerant to another?
    Brown WA; Harrison W
    Psychopharmacol Bull; 1992; 28(3):253-6. PubMed ID: 1480728
    [TBL] [Abstract][Full Text] [Related]  

  • 92. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder.
    Bisserbe J; Lane R; Flament M;
    Eur Psychiatry; 1997; 12(2):82-93. PubMed ID: 19698511
    [TBL] [Abstract][Full Text] [Related]  

  • 93. A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan.
    Kamijima K; Kuboki T; Kumano H; Burt T; Cohen G; Arano I; Hamasaki T
    Int Clin Psychopharmacol; 2005 Sep; 20(5):265-73. PubMed ID: 16096517
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Citalopram for treatment-resistant obsessive-compulsive disorder.
    Pallanti S; Quercioli L; Paiva RS; Koran LM
    Eur Psychiatry; 1999 Apr; 14(2):101-6. PubMed ID: 10572334
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.
    Pessina E; Albert U; Bogetto F; Maina G
    Int Clin Psychopharmacol; 2009 Sep; 24(5):265-9. PubMed ID: 19629012
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial.
    Dannon PN; Sasson Y; Hirschmann S; Iancu I; Grunhaus LJ; Zohar J
    Eur Neuropsychopharmacol; 2000 May; 10(3):165-9. PubMed ID: 10793318
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.
    Kordon A; Wahl K; Koch N; Zurowski B; Anlauf M; Vielhaber K; Kahl KG; Broocks A; Voderholzer U; Hohagen F
    J Clin Psychopharmacol; 2008 Oct; 28(5):550-4. PubMed ID: 18794652
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression.
    Lydiard RB; Stahl SM; Hertzman M; Harrison WM
    J Clin Psychiatry; 1997 Nov; 58(11):484-91. PubMed ID: 9413414
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder.
    Allgulander C; Dahl AA; Austin C; Morris PL; Sogaard JA; Fayyad R; Kutcher SP; Clary CM
    Am J Psychiatry; 2004 Sep; 161(9):1642-9. PubMed ID: 15337655
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs-an open-label study.
    Stryjer R; Budnik D; Ebert T; Green T; Polak L; Weizman S; Spivak B
    Clin Neuropharmacol; 2014; 37(3):79-81. PubMed ID: 24824662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.